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Abstract— Probiotic supplements have gained much 
popularity in the recent years. Media participation for the 
promotion of probiotic supplementation for various indications 
has been quite impressive as well. Traditionally, the word 
probiotic has been referred to in a positive manner and these 
supplements have been utilized as helpful resources in some way 
or another. The fact that makes this topic complicated and 
challenging, not only for the laymen but also for the healthcare 
providers is that there are numerous types and strains of 
probiotics available. Additionally, the standardization for dosing 
based on the indications is somewhat lacking. Few of the many 
questions that seem to pose challenges for today’s health care 
providers are; which probiotic, how much of it, how long to use 
for and above all is there evidence to support the use of 
probiotics. The purpose of this article is to summarize the 
available evidence for Probiotic supplements for various 
indications and attempt to scratch the surface of probiotics data 
and seek answers to the pertinent probiotics related questions. 
 
Index Terms— Probiotics, Indications, Evidence 
I. INTRODUCTION 
The World Health Organization defines probiotics as “live 
microorganisms” which when administered in adequate 
amounts confer a health benefit on the host. The most 
common types of these beneficial bacteria are Lactobacilli and 
Bifidobacterium. Previous studies indicate that probiotics may 
have a role in treating gastrointestinal illnesses, boosting 
immunity, treating and preventing some urogenital conditions, 
and preventing or slowing the development of certain types of 
cancer (1). 
As a result of lack of consensus on various aspects of 
probiotics, a joint Food and Agriculture Organization (FAO) 
of the United Nations and the World Health Organization 
(WHO) formed an expert Consultation on Health and 
Nutritional properties of Powder milk with live lactic acid 
bacteria in Argentina in October, 2001. This was the first 
meeting of this group and the focus was on evaluation of the 
available scientific evidence relating to the properties, 
benefits, functionality, safety, and nutritional features of 
probiotics. This consultation referred to probiotics as ‘Live 
microorganisms which when administered in adequate 
amounts confer a health benefit on the host’ (2). These 
probiotics/live microorganisms have been believed to play an 
important role in digestive, immunological as well as 
respiratory functions.  
The word ‘probiotic’ originated from a Greek word 





to probiotics are attributed to two scientists; A Russian born 
scientist, a noble prize winner named Eli Metchnikoff and a 
French pediatrician Henry Tissier. Metchnikoff was 
responsible for the original observation of the positive role 
played by some selected bacteria. He suggested that "The 
dependence of the intestinal microbes on the food makes it 
possible to adopt measures to modify the flora in our bodies 
and to replace the harmful microbes by useful microbes", 
Metchnikoff, 1907. Tissier observed that children with 
diarrhea had in their stools a low number of bacteria 
characterized by a peculiar, Y shaped morphology. These 
“bifid” bacteria were, on the contrary, abundant in healthy 
children He suggested that these bacteria could be 
administered to patients with diarrhea to help restore a healthy 
gut flora, Tissier, 1906 (2).  
 
Probiotic Mechanisms 
Probiotics are believed to exert their benefits on the host 
through growth and/or activity in the human body. However, 
it is not the source but the specificity of the action, of the 
microorganism that is important. As a matter of fact, 
confirming the source of a microorganism is challenging. 
Babies are not born with these bacteria in the intestine, and the 
origin of the intestinal microflora has not been fully 
elucidated. What is known is that the probiotics offer a barrier 
function for the normal microflora and this mechanism 
provides immunity against some diseases.  
Gut microbes and intestinal epithelial and immune cells 
interactions are necessary for the development and 
maintenance of intestinal homeostasis. Immune and epithelial 
responses to microbes are dependent upon the species under 
study, the concentration of microbes used and the type of cell 
studied. A barrier is maintained between luminal 
microorganisms and the host immune system through 
intestinal epithelial cells, mucus and antimicrobial production, 
and IgA secretion. This interaction with the epithelium is 
through cell surface components, extracellular secreted 
proteins and fermentation products. Host-microbial 
interactions primarily involve Toll-Like Receptors (TLR) and 
Nucleotide-Binding Ligomerization domain and leucine-rich 
repeat containing proteins. In a dose and strain dependent 
manner, several probiotic strains directly alter tight junction 
protein expression and/or localization of epithelial cells in the 
gut through the release of secreted compounds. These host-
microbial interactions at the gut mucosal surface are crucial 
for health and overall homeostasis and further, that probiotics 
may be utilized to enhance barrier and immune function to 
maintain health and offer protection against disease (3).  
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Most Common Indications and Evidence 
Probiotics have been studied for various indications 
including diseases of the Gastro Intestinal (GI) tract, 
Allergies, Urogenital tract disorders, Cancer, as well as for 
overall health benefit. Available evidence will be classified 
using the levels of recommendations A through C where; A 
Level A recommendation is based on strong, positive, well-
conducted controlled studies in the primary literature, which 
are not in abstract form. A Level B recommendation is based 
on positive controlled studies, but in the presence of some 
negative studies. A Level C recommendation is based on 
some positive studies, but clearly an inadequate amount of 
data to establish the certainty of a Level A or a Level B 
recommendation. 
 
Diarrhea: Diarrhea arising from certain pathogenic bacteria 
and viruses is treatable and preventable by the use of 
probiotics. The strongest evidence of a beneficial effect of 
defined strains of probiotics has been established using 
Lactobacillus rhamnosus GG (LGG) and Bifidobacterium 
lactis BB-12 for prevention of acute diarrhea mainly caused 
by rotaviruses in children (1). Some fungal strains from the 
Saccharomyces such as Saccharomyces Boulardii (S. 
Boulardii) have also been used.  
The most current evidence based recommendations for 
probiotics were developed based on the consensus opinion 
of the participants of the third Yale Workshop on 
probiotic use. The 2008 as well as 2011 recommendations 
from this panel (appendix a), validated the role of 
probiotics for various indications with the evidence based 
levels of recommendations as well as the probiotic strains 
(4). The recommendations for probiotic indications for 
diarrhea with the levels of recommendations are 

















B S. Boulardii, LGG 
Prevention of 
AAD 
A S. Boulardii, LGG, 
combination of L 









B/C LGG, S Boulardii 
Table I: Recommendations for Probiotic Use for 
Diarrhea 
(Developed from Recommendations of Probiotic Use 
2011, third Yale workshop) 
 
Of particular interest are the indications for diarrhea 
resulting from the use of antibiotics commonly known as 
Antibiotic Associated Diarrhea (AAD) and Clostridium 
Difficile Associated Disease (CDAD), which have 
become a growing concern in today’s health care. Several 
studies have been conducted and have proved the efficacy 
of probiotics for prevention of AAD and CDAD. Multiple 
meta-analysis as well as systematic reviews have also 
supported these results. One such metaanalysis on 
inpatient populations showed a Relative Risk Reduction 
(RRR) for AAD to be 44% meaning that use for 
probiotics can decrease the incidence of AAD by 44%. 
This reduction (RRR) for CDAD was much more 
significant at 71% (5). The studies used in this meta-
analysis used various dosages and strains of probiotics 
causing the presence of heterogeneity to the meta-
analysis.  
Another large metaanalysis of 63 RCTs, which included 11 
811 participants, indicated a statistically significant 
association of probiotic administration with reduction in AAD 
with a relative risk of 0.58 (95% CI, 0.50 to 0.68; P=.001). 
The Number needed to treat (NNT) for this study was 13 (6) 
Keeping the current available evidence for probiotics for 
the indication of diarrhea in perspective; the most effectively 
utilized strains of probiotics are; LGG, S Boulardii. The other 
Lactobacillus strains showing efficacy are; Reuteri, Casei, 
Thermophilus and Bulgaricus. 
 
Inflammatory Bowel Disease (IBD): Since the initial 
research on the treatment of chronic inflammatory bowel 
disease (IBD) with Escherichia coli Nissle1917 in 1997, 
probiotic treatment for human IBD, including pouchitis, has 
been further investigated and reviewed extensively. At 
present, collective evidence suggests that the dynamic balance 
between microbes, mainly commensal flora, and host 
defensive responses at the mucosal frontier has a pivotal role 
in the initiation and pathogenesis of chronic IBD (7). 
  Best evidence for probiotics for IBD lies with the 
combination of multiple probiotics; mainly VSL#3 which 
constitutes eight different strains of probiotics; including three 
different strains of Bifidobacterium, four strains of 
Lactobacillus and one strain of Streptococcus. 
Recommendations for probiotic usage along with the levels of 
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Crohn’s Disease C E. Coli Nisle, S. 
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Table II: Recommendation of Probiotic use for IBD 
(Developed from Recommendations of Probiotic Use 
2011, third Yale workshop) 
(VSL#3 contains 8 different strains of probiotics; 
Bifidobacterium breve, Bifidobacterium longum, 
Bifidobacterium infantis, Lactobacillus acidophilus, 
Lactobacillus plantarum, Lactobacillus paracasei, 
Lactobacillus Bulgaricus, Streptococcus thermophilus). 
 
Irritable Bowel Syndrome (IBS): The pathophysiology of 
IBS is unclear to date. However, several series of 
epidemiological, physiological, and clinical data suggest a role 
for intestinal bacteria in the pathogenesis of this disorder. 
Recent microbiology studies showed differences in the 
composition of the intestinal microbiota between patients with 
IBS and healthy individuals. Several RCT’s comparing the 
effects of probiotics versus placebo in IBS have been 
published. Despite major differences in study designs, 
probiotic species used, dosing regimens, as well as reported 
clinical end points, the current data is in support of probiotics 
for improving IBS symptoms and reducing the risk of 
persistent IBS symptoms. There is limited data on the use of 
probiotics in children with IBS; however this data is also 
suggestive for beneficial effects (8). 
 To sum up the current evidence for probiotics for IBS; the 
best recommendations are for Bifidobacterium infantis and 
animalis, VSL#3, and Lactobacillus plantarum. The 
recommended probiotics with the level of evidence are 













Table III: Recommendations for Probiotic use for IBS 
(Developed from Recommendations of Probiotic Use 2011, 
third Yale workshop) 
 
Necrotizing Enterocolitis: Is a potentially devastating disease 
affecting primarily preterm infants. It is characterized by 
severe inflammation and necrosis of the intestine. The 
mechanism of injury is believed to be the fact that the 
premature infant is likely to not have adequate initial ingestion 
of maternal vaginal and colonic flora because of rapid passage 
through the birth canal or because of C-section delivery. This 
lack of colonization with less diversity of bacteria phylla and 
fewer species of bacteria in the microbiota is implicated in 
causing the disease because of increased susceptibility to 
environmental pathogens (9). 
 The best evidence for probiotics for necrotizing 
Enterocolitis is with Lactobacillus acidophilus and 
Bifidobacterium bifidum with a level ‘B’ recommendation (4).  
 
Immune Response: The GI tract functions as a barrier against 
antigens that arise in response to microorganisms and food. 
Establishment of indigenous microflora serves as a basis for 
the generation of immunophysiologic regulation in the gut. As 
a result of this finding, novel therapeutic interventions have 
been introduced based on the consumption of cultures of 
beneficial live microorganisms that act as probiotics. One of 
the suggested mechanisms of probiotic therapy is the 
promotion of a non-immunologic gut defense barrier, which 
includes the normalization of increased intestinal permeability 
and alteration in gut micro ecology. Another possible 
mechanism of probiotic therapy is enhancement of the 
intestine’s immunologic barrier, particularly through intestinal 
immunoglobulin A responses and exclusion of intestinal 
inflammatory responses. All of these exhibit a gut-stabilizing 
effect. Many probiotic actions are mediated through immune 
regulation, particularly via balance control of anti-
inflammatory and proinflammatory cytokines. The data show 
that probiotics can be utilized as innovative tools to exclude 
intestinal inflammation, normalize mucosal dysfunction of the 
gut as well as down-regulate hypersensitivity reactions. Data 
from more recent sources suggest that differences exist in the 
way particular probiotic bacteria exert immunomodulatory 
effects.  Moreover, healthy subjects and the patients with 
inflammatory disease have distinct regulatory effects. These 
results conclude that development of clinical applications for 
extended target populations should take into consideration the 
specific immunomodulatory properties of probiotic bacteria 
(10). 
 Best evidence for probiotics for immune system 
enhancement is with LGG, Lactobacillus acidophilus, 
Lactobacillus plantarum, Bifidobacterium lactis and 
Lactobacillus johnsonii with a level ‘A’ recommendation 
(4). 
 
Allergy: The barrier function faces an abrupt change at birth 
when the gut switches from processing amniotic fluid to 
digesting milk. Release of trophic hormones occurs as a result 
of food consumption and the secretion, motility, and 
absorption functions are activated. The immunologic 
hyporesponsiveness to antigens encountered through the 
enteric route produces oral tolerance. Several 
immunoregulatory aberrations favoring sensitization instead 
of tolerance induction prevail in early infancy. Antigen 
exclusion, elimination, and immune regulation mechanisms of 
the intestine are incomplete during a variable period after 
birth. This predisposes the intestine to an aberrant antigen 
uptake. Reduced capacity to generate IgA producing cells 
occurs as a result of immature immunologic protection. T-cell 
function in aberrancy is also present, thus profound 
differences exist in immune-regulatory cytokine generation 
between the cells of infants and those of adults. In newborns, 
the cytokine profile that of humoral immunity instead of cell-
mediated immunity and the abundance of interleukin 4–
generating cells during a critical period may change the 
immunologic T-cell memory to T-helper-2 phenotype. This 
leads to increased IgE production and possibly to atopic 
sensitization (10).  
 The best evidence for probiotics for Atopic eczema 
associated with cow’s milk allergy for prevention as well as 
treatment is with LGG and Bifidobacterium lactis (4). The 
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summary of evidence with the levels of recommendation is 






















Table IV: Probiotics for prevention and treatment of Atopic 
Eczema associated with cow’s milk (Developed from 
Recommendations of Probiotic Use 2011, third Yale 
workshop) 
 
Radiation Enteritis: Results from exposure of the 
abdominal region to ionizing radiation. Many patients 
undergoing radiation are affected by transient symptoms 
of irradiation of the bowel. Acute-phase symptoms may 
last for a short time; however the long-term complications 
can include significant clinical conditions that are 
associated with high morbidity. Data from some 
experimental studies as well as the clinical trials suggest 
the potential benefit for probiotics in radiation-induced 
enteritis and colitis. Therefore, the hypothesis that 
probiotics play a role in reinforcing antioxidant defense 
systems of normal mucosal cells exposed to ionizing 
radiation may explain to an extent their beneficial action 
(11). 
 The best evidence for probiotics for radiation induced 
enteritis is with VSL#3 and lactobacillus acidophilus, with 
a ‘C’ level of recommendation (4) 
 
Bacterial Vaginosis (BV) and Vaginitis: According to 
the WHO, there is some clinical evidence to suggest that 
oral and vaginal administration of lactobacilli may 
eradicate asymptomatic and symptomatic BV. Supporting 
evidence for prevention of recurrent BV or W C by 
probiotics is limited however (12).  
 The best evidence for probiotics for Vaginosis and 
vaginitis is with Lactobacillus acidophilus, LGG and 
Lactobacillus Reuteri with a ‘C’ level recommendation 
(4). 
 
Urogenital Tract Disorders: The association between 
abnormal vaginal microbial flora and its formidable risk in 
the increased incidence of urinary tract infection (UTI) 
underscores the value of understanding the microbial flora 
and the efforts needed to maintain it, to ensure urogenital 
health. Surprisingly in spite of the high incidence, UTI’s 
receive very little attention from the medical fraternity. 
Growing awareness among common men as well as the 
newer advances in the medical field has brought them 
some attention. The significance of replenishing this 
depleting microbial flora with 'probiotics' has resurfaced 
in a big way. It would be unfair to take the value of 
probiotics on their face value. While probiotics cannot be 
considered a panacea for treating UTI’s, the available data 
may be promising for ptobiotics as a strong option in 
improving and maintaining urogenital health (13). 
 The evidence for probiotics for urogenital tract 
disorders is inconclusive at this time and more research is 
needed to support this indication. 
 
Coronary Artery Disease (CAD): Probiotics are 
believed to exert this benefit by lowering cholesterol. 
Suggested mechanisms for cholesterol removal by 
probiotics are; assimilation of cholesterol by growing 
cells, binding of cholesterol to cellular surface, 
incorporation of cholesterol into the cellular membrane, 
de-conjugation of bile via bile salt hydrolase, co-
precipitation of cholesterol with de-conjugated bile, 
binding action of bile by fiber, and production of short-
chain fatty acids by oligosaccharides.  
More RCT’s are needed to evaluate the 
cholesterol lowering properties of probiotics. 
Bifidobacterium and Lactobacillus species could 
potentially be studied and utilized for this indication (14). 
 
Ventilator Associated Pneumonia: A recent 
metaanalysis of seven RCT’s including total of 1,142 
patients showed no significance of probiotics use for 
prevention of Ventilator Associated Pneumonia (VAP). 
The study showed Odds ratio (OR) for VAP to be 0.82; 
95% CI (confidence interval), 0.55 to 1.24; P = .35, with 
low heterogeneity among the studies (I2 = 36.5%, P = 
.15). This study was consistent with the previously 
available evidence and did not appear to significantly alter 
any of the other meta-analysis endpoints (15).  
Therefore, the use of Probiotics for prevention of VAP 
cannot be recommended at this time. Current literature is 
against the use of probiotics for prevention of VAP. 
 
Colon Cancer: Preliminary evidence suggests that 
probiotic microorganisms may be able to prevent or delay 
the onset of certain cancers. This originates from the 
knowledge that members of the gut microflora are capable 
of producing carcinogens such as nitrosamines. Hence, 
administration of Lactobacilli and Bifidobacteria could 
theoretically modify the flora resulting in decreased 
glucuronidase and carcinogen levels. Furthermore, there is 
some evidence that suggest that the cancer recurrences at 
other sites, such as the urinary bladder may be reduced by 
intestinal instillation of probiotics including Lactobacilus 
casei. In vitro studies with LGG and Bifidobacteria and an 
in vivo study using two other Lactobacilus rhamnosus 
strains and propionibacterium species showed a decrease 
in availability of carcinogens in the lumen of the gut.  
Keeping all the above in perspective, it would be interesting 
to follow the future research for probiotics for this indication. 
It is too early to make a definitive clinical conclusion 
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regarding the efficacy of probiotics in cancer prevention at 
this time (4) 
 
Healthy People:  Otherwise healthy consumers also use 
probiotics based on the assumption that probiotics can 
help retains their health and well-being, and potentially 
decrease their long-term risk of disease states affecting the 
bowel, kidney, respiratory tract and heart. There is a 
possibility that probiotic microorganisms could become 
primary colonizers that could remain long-term or even 
for life. While the use probiotic in premature and low 
birth weight infants may prevent death and serious 
morbidity, the alteration of flora in otherwise healthy 
babies is a more complex issue and needs further 
investigation (2) 
 It would also be prudent to recognize that the dosages 
of probiotics may not be sufficient in many commercially 
marketed yogurt brands. Clinicians should use 
manufacturer’s recommendations for dosing of specific 
probiotics for various indications. 
 
Most Common Probiotics Genera and Adverse Events 
The Agency for Healthcare Research and Quality’s 
(AHRQ) systematic review on the safety of products 
containing microorganisms believed to have probiotic 
properties. This review was co-sponsored by the National 
Institutes of Health (NIH) Office of Dietary Supplements, the 
NIH National Center for Complementary and Alternative 
Medicine (NCCAM), and the Food and Drug Administration 
(FDA) Center for Food Safety and Applied Nutrition. This 
document was a result of a systematic evidence based review 
of the studies monitoring the adverse health outcomes among 
probiotic studies, without restriction due to study design, 
participant, or clinical field. As per this report, the six genera 
of probiotics; Lactobacillus, Bifidobacterium, Saccharomyces, 
Streptococcus, Enterococcus and Bacillus have been studied. 
Lactobacillus alone or in combination with other genera most 
commonly and Bifidobacterium were the most studied 
probiotics. There was some evidence to indicate that 
Streptococcus interventions may be responsible for a greater 
number of adverse events compared to other genera. There are 
no head to head trials to prove this however. The reviewers 
stratified RCTs that used each genus exclusively, no 
statistically significant difference between intervention and 
control group participants was observed for any of the six 
genera. However, published reports on the genera 
Enterococcus, Bacillus, Streptococcus were not available in 
the literature. Saccharomyces interventions and 
Bifidobacterium interventions were also rare, and a substantial 
proportion of studies were done using blends of probiotics 
(16). 
 
Adverse Events: Most reported side effects were GI side 
effects and most of these side effects were observed within the 
first 3 days of treatment. There have been some case reports of 
infections including sepsis, bacteremia and fungemia believed 
to be resulting from probiotics. Most infections seem to be 
occurring one week to several weeks after initiation of 
probiotic use. Interestingly, during the subgroup analyses, 
there was no statistical significance that participants using 
probiotic organisms experienced more GI side effects, or 
infections compared with control group participants (see table 




















Table V: Data from AHRQ Subgroup analyses of Adverse 
Effects 
 
Interactions with Other Medications:  The classes of 
medications that have been suspected to have interactions with 
probiotics in the past include; corticosteroids, antibiotics, 
immune suppressants, dietary therapies, chemotherapy, these 
have been questioned about possibly influencing the adverse 
events experienced by individuals taking medications from the 
above mentioned classes along with the probiotics. The 
current data suggests that the relative risk to experience an 
adverse event for studies with co-treatments is slightly higher 
but not of any statistical significance. Upon an interaction 
analysis of 44 studies with co-treatments the findings were as 
follows; Relative Risk (RR) =1.12; 95% CI: 0.99-1.26; 
p=0.074.  
 
Adverse Events based on Age groups: Stratified analyses 
and meta-regressions did not show any increased risk of 
adverse events for children, adults, or elderly participants 
compared with adverse events observed in corresponding 
control groups. There were only four studies on the elderly 






























Table VI: Data from AHRQ Stratified analyses & 
metaregressions of adverse events by age groups 
 
Adverse Events Based on Health Status: Health status 
has traditionally been thought to be associated with the 
experience of an adverse event when using probiotics. 
Case reports of serious adverse events appeared to be 
individuals with health-compromised status.  Healthy 
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participants were not generally affected by serious 
infections caused by probiotic organisms. Therefore 
subgroup analyses of RCTs in medium health-
compromised participants and critically ill patients was 
conducted and the results did not show a statistically 
significant increased risk of experiencing adverse events 
for intervention participants compared with control group 
participants with similar patient characteristics (see table 
VII) (16). 
 







Critically Ill 0.79 0.51-
1.22 
0.286 
Table VII: Data from AHRQ subgroup analyses of RCT’s 
in medium health compromised and critically ill patients 
 
Adverse Events Based On Routes of Administration: Most 
common routes of administration of probiotics are oral and 
enteral. Intra vaginal and topical routes have also been used.  
Oral route has been the most common routes of 
administration. During a stratified analysis, there was 
statistical difference found between the control and placebo 
groups. The relative risk of adverse events for probiotics 
group participants compared to control group participants was 
0.98 (95% CI: 0.93-1.04; p=0.581). The corresponding risk 
difference between groups was also not statistically significant 
at-0.001 (95% CI: 0.005-0.003; p=0.207) (16). 
Enteral routes of administration include naso-gastric 
and jejunostomy feeding tubes. The difference between the 
probiotic and control groups was not of any statistical 
significance when a pooled analysis based on adverse events 
was conducted. Results showed; RR= 0.84 (95% CI= 0.55-
1.29; p=0.350), RD -0.002; 95% CI: -0.022, 0.017; p=0.828) 
(16). 
Other routes of administration included intra-vaginal 
administration of probiotics which revealed mild-moderate 
additional side effects such as vaginal discharge. RR 1.06 
(95% CI: 0.72-1.57), p=0.761 and RD -0.004 (95% CI: -
0.054-0.046), p=0.870) (16).   
Therefore, there was no evidence that a particular 
mechanism or route of administration of probiotic organisms 
was associated with an increased risk of an adverse event in 
intervention participants relative to control group participants 
(16). 
 
Single versus Multiple Probiotics: The next question is 
whether to use one single strain of probiotics or a combination 
of multiple strains. The reality is that the combination of 
probiotics is used more frequently than the single probiotic 
and hence majority of the studies have conducted using 
combination of probiotics. A Meta Regression to investigate if 
the risk of adverse events was different among these two 
groups across studies. There was no statistically significant 
difference, showing a RR=0.93 (95% CI=0.82-1.04), p=0.205 
(16). 
Duration of Use of Probiotics: Duration of use of probiotics 
for a short term (<1month), medium term (>1 month-<1year), 
and long-term (1 year or more) has also been compared for the 
presence of adverse events among probiotics and control 
groups. Stratified analyses and metaregression was undertaken 
to explore whether the duration of intervention was associated 
with encountered adverse events. Short term and Medium 
term use seemed to have no statistically significant difference 
in encountered adverse events.  The difference in adverse 
events was also not statistically significant in the long term 
use groups. RR and RD (Risk Difference) are presented in 
table VIII. An interesting finding was an isolated case report 
of a participant who took Saccharomyces Boulardii for over a 
year presented with a fever of unknown origin (FUO). 














Long term (1 year 
or more) 




Table VIII: Data from AHRQ stratified analyses of Adverse 
Events based on the duration of Use of probiotics 
 
Based on the available evidence, it would be 
reasonable to say that the increased duration of use of 
probiotics did not increase the incidence of adverse events 
with less than one year of use of probiotics. It would be 
prudent to use some caution if the use requires over one 
year and the decision should be based on the indication as 
well as the benefits versus risks.  
 
Storage and Safety: Even though the use of the term 
“probiotic” has traditionally been limited to 
microorganisms alive at the time of consumption, it is 
becoming increasingly evident that even non-viable 
microorganisms can confer health benefits as well (17). 
Non-viable forms offer the benefit of being 
stable for prolonged periods of time as compared with the 
viable products. It is questionable, however, that all health 
benefits achievable by live probiotics can be achieved by 
non-viable forms. It is known that one strain of 
Lactobacillus; johnsonii is effective in reducing the 
activity of gastric pathogen Helicobacter (H) pylori in a 
fermented form but not in a pasteurized form (18). In 
addition to pasteurization, other methods used to prepare 
these non-viable forms include; sonication, high pressure 
treatment, and freeze thawing. Irradiation is used as well 
however that method is not permitted for use in food.  
Probiotics stability during manufacturing and 
storage is dependent upon three major factors; strain 
robustness, process and storage conditions. Growing 
probiotics in an industrial medium and drying them for 
longer lasting storage is a common method used to 
improve stability by controlling the moisture content. 
Therefore, most liquid probiotic products are refrigerated 
products. The stability of probiotic-containing chilled 
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dairy products is well known. Products have been reported 
to maintain potency up-to 4–6 weeks of refrigerated 
storage. The shelf like improves with the drying process. 
The drying step represents a relatively short period during 
which probiotics are exposed to stressful conditions. 
Afterwards, they still have to remain viable in the final 
product for up to two years of storage. Depending on the 
conditions of storage and duration, the loss of probiotic 
viability during storage may be significantly higher than 
the loss during the drying process. Details of stability and 
storage temperatures for various probiotic forms are 





























































Table IX: Moisture content and temperature of various 
dehydrated products (19) 
Summary 
 Current evidence suggests that use of probiotics is 
promising in prevention and or treatment of;  GI diseases 
including; Infectious diarrhea, Pouchitis, Irritable Bowel 
Syndrome, Helicobacter pylori, Clostridium difficile 
Disease, Antibiotic Associated Diarrhea, Traveler's 
Diarrhea, or Necrotizing Enterocolitis (21). Evidence also 
supports use with less strength than the conditions 
mentioned above, including; the conditions of the 
urogenital tract, allergy, cholesterol lowering, as well as 
cancer prevention. More research is needed to evaluate 
efficacy for these indications for a superior evidence. The 
mechanisms of actions of probiotics on GI and various 
other conditions have been studied and will continue to be 
studied with the same pharmacologic approach as drugs 
(22). Clinicians must record patient’s use of probiotics in 
the medication profiles and be vigilant and report any 
adverse events that may arise from their use. With the 
growing use of probiotics among general population for 
various indications, it would be prudent to enquire about 
use of probiotics in patient history and educate patients on 
storage, safety as well as monitoring for any adverse 
events during their use of probiotics. Clinician’s should 
use current evidence and their clinical judgment in making 
recommendations for or against the use of probiotics. 
Ultimately, while selecting a product for use, the benefits 
should outweigh the risks. 
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